{"id":196271,"date":"2026-08-11T11:39:34","date_gmt":"2026-08-11T06:09:34","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=196271"},"modified":"2026-08-11T11:39:34","modified_gmt":"2026-08-11T06:09:34","slug":"beta-drugs-ltd-share-price-near-52-week-high-2026-08-11","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/beta-drugs-ltd-share-price-near-52-week-high-2026-08-11\/","title":{"rendered":"Beta Drugs Ltd. (BETA) Share Price Trades Within 2% of 52-Week High"},"content":{"rendered":"<style id=\"univest-disable-toc\">#ez-toc-container,.ez-toc-container,.lwptoc,.toc_container,.wp-block-rank-math-toc-block{display:none!important}<\/style>\n<p style=\"margin-top:0!important;margin-bottom:0!important;\"><a href=\"https:\/\/univest.in\/stocks\/beta\/beta-drugs-ltd-share-price-today\">Beta Drugs Ltd.<\/a> Share Price is Rs 2,628, placing the stock within 2% of its 52-week high. The company\u2019s market capitalisation stands at Rs 2,631.45 crore.<\/p>\n<p style=\"margin-top:0!important;\">Beta Drugs Ltd. Share Price was at Rs 2,628 at the time of qualification on 11 August 2026 at 11:30:38 AM IST, with the stock trading within 2% of its 52-week high. With a market capitalisation of Rs 2,631.45 crore, the move has put the counter back on the radar for investors scanning for stocks near their one-year peak. The supplied Univest screener data confirms the proximity event, which is often watched because stocks trading close to yearly highs can signal sustained market interest even before any confirmed breakout.<\/p>\n<p>In this case, the data establishes the price position clearly: Beta Drugs Ltd. Share Price Today is hovering close to an important long-term reference zone. It does not, however, establish a company-specific catalyst behind the move. That makes the broader numerical context more important. Beta Drugs Ltd. Share Price is now being evaluated not only for price strength but also for valuation, profitability and how the company compares with other listed pharmaceutical names in the Healthcare space. Using only verified figures from Univest, the analysis below looks at what is supporting investor attention and what metrics deserve closer monitoring.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Beta_Drugs_Ltd_Share_Price_Today_Within_2_of_52-Week_High\"><\/span><strong>Beta Drugs Ltd. Share Price Today: Within 2% of 52-Week High<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>LTP at 2% Qualification<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 2,628<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 2,631.45 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>52-Week High Position<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Trading within 2% of its 52-week high<\/td>\n<\/tr>\n<\/table>\n<p>Beta Drugs Ltd. (BETA) traded at Rs 2,628. Reported volume was 0.<\/p>\n<p>Beta Drugs Ltd. Share Price Today stands at Rs 2,628 based on the event-time last traded price captured by the Univest screener. The same verified dataset identifies the stock as trading within 2% of its 52-week high, placing it close to its one-year peak and naturally drawing attention from momentum-focused as well as fundamentally oriented market participants. When a stock stays in this zone, the market usually treats it as an important reference area because it reflects how strongly buyers have been willing to value the business over the past year.<\/p>\n<p>For Beta Drugs Ltd. Share Price, the immediate takeaway is not that the stock has crossed a major barrier, but that it remains within striking distance of one. That distinction matters. The screener confirms proximity only, and investors should read it as a sign of attention rather than a confirmed breakout event. Still, Beta Drugs Ltd. Share Price near a yearly high often becomes part of broader stock news coverage because this kind of positioning can concentrate interest around valuation, relative strength and sector comparison.<\/p>\n<p>Another reason the move matters is company size. At Rs 2,631.45 crore in market capitalisation, Beta Drugs Ltd. Share Price is not being watched as a tiny illiquid micro-cap statistical outlier. Instead, it sits near the upper end of the market-cap range of many same-industry companies supplied in the Univest dataset. That increases the relevance of this price setup. From here, the next step is to assess whether the underlying fundamentals justify why Beta Drugs Ltd. Share Price is being tracked so closely near its 52-week high.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Beta_Drugs_Ltd_BETA_Fundamental_Analysis\"><\/span><strong>Beta Drugs Ltd. (BETA) Fundamental Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 2,631.45 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>P\/E Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">66.92x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>P\/B Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">10.59x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">18.65%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">22.17%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>EPS<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 37.42<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Book Value Per Share<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 236.52<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Dividend Yield<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">0%<\/td>\n<\/tr>\n<\/table>\n<p>Beta Drugs Ltd. was valued at a P\/E ratio of 66.92x, a P\/B ratio of 10.59x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.<\/p>\n<p>Profitability and capital efficiency were represented by ROE of 18.65% and ROCE of 22.17%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.<\/p>\n<p>Per-share and shareholder-return metrics included EPS of Rs 37.42, book value per share of Rs 236.52, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Sector_and_Industry_Context\"><\/span><strong>Sector and Industry Context<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Sector<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Healthcare<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Industry<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Pharmaceuticals &amp; Drugs<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Scope<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">same industry<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company P\/E Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">66.92x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median P\/E<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">18.46x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Average P\/E<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">52.48x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark P\/E Range<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">0x to 3,396.3x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company P\/B Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">10.59x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median P\/B<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">1.78x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">18.65%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">10.21%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">22.17%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">12.96%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 2,631.45 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median Market Cap<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 146.63 crore<\/td>\n<\/tr>\n<\/table>\n<p>Beta Drugs Ltd. (BETA) is classified under sector: Healthcare and industry: Pharmaceuticals &amp; Drugs.<\/p>\n<p>Beta Drugs Ltd. (BETA) has a P\/E ratio of 66.92x, which is above the benchmark median of 18.46x, a difference of +262.51%. P\/E is a valuation multiple and is not, by itself, a buy or sell signal.<\/p>\n<p>Beta Drugs Ltd. (BETA) has a ROE of 18.65%, which is above the benchmark median of 10.21%, a difference of +82.66%. Beta Drugs Ltd. (BETA) has a ROCE of 22.17%, which is above the benchmark median of 12.96%, a difference of +71.06%.<\/p>\n<p>Track stocks reaching yearly peaks through the <a href=\"https:\/\/univest.in\/screeners\/52-week-high\">Univest 52-week-high screener<\/a>. The peer table below provides the company-level comparison.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Peer_Comparison\"><\/span><strong>Peer Comparison<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Company<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Symbol<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Market Cap (Cr)<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">P\/E<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">P\/B<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">ROE (%)<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">ROCE (%)<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/kpl\/kwality-pharmaceuticals-ltd-share-price-today\"><strong>Kwality Pharmaceuticals Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">KPL<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2,707.2<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">40.09<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">9.77<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">28.21<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">26.35<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/saiparent\/sai-parenteral-s-ltd-share-price-today\"><strong>Sai Parenteral&#39;s Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">SAIPARENT<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2,513.58<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">181.97<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">3.36<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">13.9<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">12.97<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/nglfine\/ngl-fine-chem-ltd-share-price-today\"><strong>NGL Fine-Chem Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">NGLFINE<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2,118.6<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">44.48<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">6.5<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">27.9<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">33.91<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/venusrem\/venus-remedies-ltd-share-price-today\"><strong>Venus Remedies Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">VENUSREM-BE<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2,068.61<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">17.49<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2.96<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">9.85<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">7.89<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/hesterbio\/hester-biosciences-ltd-share-price-today\"><strong>Hester Biosciences Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">HESTERBIO<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2,057.85<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">15.63<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">4.68<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">16.17<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">14.12<\/td>\n<\/tr>\n<\/table>\n<p>Beta Drugs Ltd. (BETA) has a P\/E ratio of 66.92x compared with the displayed peer median of 40.09x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 18.65% compares with a peer median of 16.17% across the companies shown in the table. ROCE stood at 22.17% versus the displayed peer median of 14.12%, providing a capital-efficiency comparison. Beta Drugs Ltd. (BETA) has a market capitalisation of Rs 2,631.45 crore. Among the 5 peers shown, 1 have a larger market capitalisation.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Why_Investors_Are_Watching_Beta_Drugs_Ltd\"><\/span><strong>Why Investors Are Watching Beta Drugs Ltd.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Beta Drugs Ltd. Share Price is at Rs 2,628 and the Univest screener identifies it as trading within 2% of its 52-week high.<\/li>\n<li>The company has a market capitalisation of Rs 2,631.45 crore, putting it near the larger end of the supplied same-industry comparison set.<\/li>\n<li>Valuation is rich, with P\/E at 66.92 and P\/B at 10.59, both above same-industry median and average levels.<\/li>\n<li>Profitability is stronger than benchmark middle levels, with ROE at 18.65 and ROCE at 22.17.<\/li>\n<li>Peer comparisons show Beta Drugs Ltd. Share Price trades at a premium to several pharmaceutical names, keeping focus on whether returns justify that premium.<\/li>\n<\/ul>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"About_Beta_Drugs_Ltd\"><\/span><strong>About Beta Drugs Ltd.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Beta Drugs Ltd. operates in the Healthcare sector and is classified within the Pharmaceuticals &amp; Drugs industry. Based on the supplied dataset, the company is part of a listed pharmaceutical peer group that includes names such as Kwality Pharmaceuticals, NGL Fine-Chem, Venus Remedies and Hester Biosciences. That industry positioning matters because Beta Drugs Ltd. Share Price is being judged not in isolation, but against a large same-industry universe of 136 companies.<\/p>\n<p>From a market perspective, Beta Drugs Ltd. is a mid-sized listed healthcare company with a market capitalisation of Rs 2,631.45 crore. The stock\u2019s current market attention comes from a mix of premium valuation, above-benchmark return ratios and its position close to the 52-week high. For readers tracking Beta Drugs Ltd. Stock News, the most relevant company context available in the verified data is its place within the Pharmaceuticals &amp; Drugs segment, where valuation and capital efficiency comparisons are central to how the market assesses quality and relative pricing.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Track_Beta_Drugs_Ltd_Share_Price_on_Univest\"><\/span><strong>Track Beta Drugs Ltd. Share Price on Univest<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Use <a href=\"https:\/\/univest.in\/stocks\/beta\/beta-drugs-ltd-share-price-today\">Beta Drugs Ltd. (BETA) live share-price page<\/a>, <a href=\"https:\/\/univest.in\/screeners\/52-week-high\">Univest 52-week-high screener<\/a>, <a href=\"https:\/\/univest.in\/blogs\">Univest market blogs<\/a> to review live stock data, yearly-high lists and related market analysis.<\/p>\n<p>Investors tracking Beta Drugs Ltd. Share Price can use Univest to follow live price movements, 52-week levels, valuation ratios, profitability metrics and sector comparisons in one place. Univest also helps users monitor Beta Drugs Ltd. Share Price Today alongside peer data, market capitalisation trends and benchmark context from the broader Pharmaceuticals &amp; Drugs industry.<\/p>\n<p>For readers who want to keep Beta Drugs Ltd. Share Price under watch after this near-52-week-high screen, Univest provides a structured way to compare the stock\u2019s P\/E, P\/B, ROE, ROCE, EPS, book value and dividend yield with listed peers and industry medians. That is especially useful when a stock is close to a one-year high and the market\u2019s attention shifts from pure price action to whether fundamentals support continued interest.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Beta_Drugs_Ltd_Share_Price_today\"><\/span><strong>What is Beta Drugs Ltd. Share Price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Beta Drugs Ltd. Share Price was Rs 2,628 at the event qualification time on 11 August 2026 at 11:30:38 AM IST. The same Univest screener reading placed the stock within 2% of its 52-week high.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Beta_Drugs_Ltd_Share_Price_in_focus_today\"><\/span><strong>Why is Beta Drugs Ltd. Share Price in focus today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Beta Drugs Ltd. Share Price is in focus because the stock is trading within 2% of its 52-week high. With a market capitalisation of Rs 2,631.45 crore, that proximity has increased market attention.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Beta_Drugs_Ltd_Share_Price_expensive_compared_with_its_industry\"><\/span><strong>Is Beta Drugs Ltd. Share Price expensive compared with its industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> On supplied numbers, Beta Drugs Ltd. Share Price looks richly valued versus its same-industry benchmark. Its P\/E is 66.92 against the industry median of 18.46, while its P\/B is 10.59 versus 1.78.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_profitable_is_Beta_Drugs_Ltd_based_on_current_ratios\"><\/span><strong>How profitable is Beta Drugs Ltd. based on current ratios?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Profitability metrics are relatively strong in the supplied dataset. Beta Drugs Ltd. reports ROE of 18.65 and ROCE of 22.17, both above same-industry median levels of 10.21 and 12.96 respectively.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_do_EPS_book_value_and_dividend_yield_show_for_Beta_Drugs_Ltd\"><\/span><strong>What do EPS, book value and dividend yield show for Beta Drugs Ltd.?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Beta Drugs Ltd. has EPS of Rs 37.42 and book value per share of Rs 236.52, indicating earnings and accounting net worth per share. The dividend yield is 0, so yield is not a current support factor.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_large_is_Beta_Drugs_Ltd_within_its_industry_universe\"><\/span><strong>How large is Beta Drugs Ltd. within its industry universe?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Beta Drugs Ltd. has a market capitalisation of Rs 2,631.45 crore. That is well above the same-industry median of Rs 146.63 crore and average of Rs 484.34 crore across the 136-company benchmark universe.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_Beta_Drugs_Ltd_compare_with_Kwality_Pharmaceuticals\"><\/span><strong>How does Beta Drugs Ltd. compare with Kwality Pharmaceuticals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Beta Drugs Ltd. trades at P\/E of 66.92 versus Kwality Pharmaceuticals at 40.09, with similar market capitalisation. However, Kwality shows stronger profitability, with ROE of 28.21 and ROCE of 26.35 versus Beta Drugs\u2019 18.65 and 22.17.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_Beta_Drugs_Ltd_compare_with_NGL_Fine-Chem\"><\/span><strong>How does Beta Drugs Ltd. compare with NGL Fine-Chem?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Beta Drugs Ltd. carries higher valuation multiples than NGL Fine-Chem, with P\/E of 66.92 versus 44.48 and P\/B of 10.59 versus 6.5. NGL Fine-Chem, however, reports stronger ROE and ROCE than Beta Drugs.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_sector_does_Beta_Drugs_Ltd_belong_to\"><\/span><strong>What sector does Beta Drugs Ltd. belong to?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Beta Drugs Ltd. belongs to the Healthcare sector and is classified under the Pharmaceuticals &amp; Drugs industry. The sector comparison in this article uses a same-industry benchmark set covering 136 listed companies.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_investors_track_Beta_Drugs_Ltd_Share_Price_and_related_metrics\"><\/span><strong>Where can investors track Beta Drugs Ltd. Share Price and related metrics?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors can track Beta Drugs Ltd. Share Price on Univest for live price updates, 52-week levels, valuation ratios, profitability metrics and peer comparisons. That helps place day-to-day market moves in a broader analytical context.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Beta Drugs Ltd. Share Price trades within 2% of its 52-week high at Rs 2,628. Market cap stands at Rs 2,631.45 crore.<\/p>\n","protected":false},"author":29,"featured_media":196269,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-196271","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["196269"],"rank_math_title":["Beta Drugs Ltd. Share Price and 52-Week High Stock Analysis"],"rank_math_description":["Beta Drugs Ltd. Share Price is within 2% of its 52-week high at Rs 2,628. Explore valuation, profitability, sector and peer analysis."],"rank_math_focus_keyword":["Beta Drugs Ltd. Share Price"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/Beta_Drugs_Ltd_BETA_Share_Price_Trades_Within_2_of_52_Week_High_bullish.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/196271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=196271"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/196271\/revisions"}],"predecessor-version":[{"id":196273,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/196271\/revisions\/196273"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/196269"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=196271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=196271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=196271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}